Released Nov 10, 2011, after the close
10-Q filed Nov 10, 2011, 41 days after period end · 0001144204-11-062961
Q3 2010 · 10-Q
Revenue$2.18M$2.18M −86.8% vs Q3 2009−1.5% vs Q2 2010
Net Income-$7.35M-$7.35M N/M vs Q3 2009N/M vs Q2 2010
EPS Diluted-$0.08-$0.08 N/M vs Q3 2009N/M vs Q2 2010
Gross Profit$285,679−94.6%
Operating Income-$7,230,450N/M
Operating Cash Flowderived-$4,256,911N/M
Free Cash Flowderived-$4,375,786N/M
Margins · derived
Gross margin13.1%−18.7 pt vs Q3 2009
Operating margin-332.1%−297.3 pt vs Q3 2009
Net margin-337.5%−294.1 pt vs Q3 2009
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2010 | Q3 2009 |
|---|---|---|
| Revenue | $2.18M | $16.48M |
| Net Income | -$7.35M | -$7.14M |
| EPS Diluted | -$0.08 | -$0.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lisata Therapeutics, Inc. · CIK 320017 · Engraved from SEC EDGAR